Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur–Uracil Plus Leucovorin Versus Capecitabine

Tashiro, Jun; Yamaguchi, Shigeki; Ishii, Toshimasa; Kondo, Hiroka; Hara, Kiyoka; Shimizu, Hiroki; Takemoto, Kazuo; Suzuki, Atsushi

doi:10.1016/j.clcc.2017.01.006

Cited by 5 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our database search identified 2341 publications after removal of duplicates. After an initial screen, 205 articles were reviewed in full, from which 34 studies (9 randomized trials 1 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 and 25 observational studies 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 ) were deemed eligible for inclusion. There was strong agreement between the 2 reviewers at both the initial screen and the full-text screen (percentage agreement >90% and κ > 0.6).…”

Section: Resultsmentioning

confidence: 99%

“…Specifically, we excluded the studies by Ahn et al 25 and by Yaich et al 47 because we were unable to obtain an effect estimate suitable for inclusion in the meta-analysis and we were unable to reach these authors for further details regarding their findings. In addition, we excluded the studies by Satkunam et al 40 and by Tashiro et al 43 due to clinical heterogeneity in the exposure definition. Specifically, these researchers did not strictly examine the duration of the prescribed chemotherapy regimen; rather, they studied a composite exposure that included dose reductions and dose modifications, such as a periodic dose omission.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer

et al. 2019

View full text Add to dashboard Cite

Key Points Question Are shortened durations of adjuvant chemotherapy associated with decreased survival among patients with stage II and III colon cancer? Findings In this systematic review and meta-analysis of 22 studies comprising 43 671 patients, shortened durations of adjuvant chemotherapy were not associated with worse survival in studies involving combination regimens (the current standard of care) among patients with stage III colon cancer. Conversely, the standard 6 months of chemotherapy was associated with improved survival among patients prescribed monotherapy. Meaning Shorter durations of adjuvant chemotherapy may not adversely alter survival among patients with stage III colon cancer treated with combination therapy; patients prescribed monotherapy should be encouraged to complete the entire 6 months of treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Acceptable toxicities and compliance were observed in the patients with stage III colon cancer when administered eight courses of capecitabine with a dose of 1250 mg/m 2 orally, twice daily, on days 1–14, every 21 days [15, 16]. Enlightened by the results of the IDEA trial, we hypothesized that a modified XELOX (mXELOX) adjuvant chemotherapy with 6 cycles of oxaliplatin and a full cycle of capecitabine might have comparable efficacy with acceptable toxicities compared with the 6-month standard XELOX adjuvant chemotherapy regimen for patients with stage III colon cancer, particularly in the high-risk subgroup.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single‐center experience

Peng

Zhang

et al. 2019

Cancer Communications

View full text Add to dashboard Cite

BackgroundA fixed 8-cycle oxaliplatin and capecitabine (XELOX) regimen has been the standard adjuvant therapy for patients with stage III colon cancer. However, completing the full-cycle of oxaliplatin is often associated with severe neurotoxicity. To spare patients from the toxic effects, without comprising the required efficacy, we evaluated the safety and efficacy of a modified XELOX (mXELOX) adjuvant chemotherapy regimen with 6 cycles of oxaliplatin and a full cycle of capecitabine.MethodsWe retrospectively analyzed 330 eligible patients with stage III colon cancer who underwent curative tumor resection followed by mXELOX, standard XELOX or unfinished XELOX adjuvant chemotherapy between December 2007 and April 2015. Associated prognostic factors were investigated and their disease-free survival (DFS) and overall survival (OS) rates were also determined and compared among the different regimen groups.ResultsCompared with the standard XELOX group, the mXELOX group had lower total incidence rates of neurotoxicity (39.3% vs. 76.2%, P < 0.001), leucopenia (53.6% vs. 69.8%, P = 0.017) and thrombocytopenia (38.1% vs. 56.3%, P = 0.011). The standard XELOX and mXELOX adjuvant chemotherapy regimens presented with comparable 3-year DFS rates (86.3% vs. 89.2%; P = 0.838) and 3-year OS rates (92.7% vs. 97.6%; P = 0.227). Compared to unfinished XELOX chemotherapy, the oncologic benefits of the mXELOX regimen were greater for patients with T4 tumors (3-year DFS: Hazard ratio [HR], 2.184; 95% confidence interval [CI], 1.051–4.540; P = 0.036; 3-year OS: HR, 4.529; 95% CI 1.245–16.479; P = 0.022) and for high-risk patients (3-year DFS: HR, 1.962; 95% CI 0.964–3.993; P = 0.044; 3-year OS: HR, 4.193; 95% CI 1.182–14.874; P = 0.026).ConclusionsThe mXELOX adjuvant chemotherapy presented a comparable survival benefit and lower incidence of toxicity than standard XELOX chemotherapy. It could be an alternative treatment for high-risk patients with operated stage III colon cancer.

show abstract

An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report

Hiraki

Tanaka

Koga

et al. 2019

J Gastrointest Canc

View full text Add to dashboard Cite

Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur–Uracil Plus Leucovorin Versus Capecitabine

Abstract: The 3-year RFS and OS were similar for both regimens, yielding an excellent outcome. The selection of adjuvant chemotherapeutic regimens must be based on the patient's status as well as considering the incidences of adverse events, medical cost, and administration convenience.

Cited by 5 publications

References 18 publications

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single‐center experience

An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report

Contact Info

Product

Resources

About